Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics Inc. (AXSM) Q2 Earnings Cheat Sheet
- Axsome Therapeutics initiated with a Buy at Needham
- Axsome Therapeutics price target lowered to $95 from $97 at BofA
- Biotech Alert: Searches spiking for these stocks today
- Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
Questions or Comments about the article? Write to editor@tipranks.com